172 search results for: type 2 inflammation
ADVENT On Air | The Road Ahead: Achieving Remission for Patients With Asthma
Join Professors Klaus Rabe and Ian Pavord as they discuss the importance of on-treatment clinical remission as a goal in asthma management.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Prurigo Nodularis (PN): Understanding Its Clinical Features, Complex Burden, and Underlying Mechanisms
Explore the clinical features, complex burden, and underlying mechanisms of PN.
The Role of IL-4 and IL-13 in the Pathophysiology of CSU
Dr. Jason Hawkes details the role of IL-4 and IL-13 in the pathophysiology of CSU at EADV 2025
Neuroimmune Dysfunction Is Critical in the Pathophysiology of Prurigo Nodularis
Dr. Sarina Elmariah explains the importance of neuroimmune crosstalk in the development of prurigo nodularis.
Emerging Therapeutics: Addressing the Gaps in CSU Patient Care
In this video from EADV 2025, Professor Metz shares exciting data from therapies recently approved or in late-stage development for CSU.
The Evolving Toolbox: Current Approaches in BP Management
Professor Dédée Murrell shares recent advances in the therapeutic landscape for BP in this video from EADV 2025
Bullous Pemphigoid: Insights and Innovation
Watch Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap at EADV 2025 as they explore the clinical presentation and diagnosis of BP and break down the underlying pathophysiology including the roles of autoimmunity and key inflammatory pathways such as Type 2 inflammation. The experts also discuss the evolving therapeutic landscape and how new insights are shaping future treatment strategies.
Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.
New Horizons: The Emergence of Targeted Therapies
In this ADVENT symposium at the 2024 EADV meeting, Professor Dedee Murrell reviews the current treatment guidelines for bullous pemphigoid (BP) and the emergence of targeted therapies including a highlight of the LIBERTY-BP ADEPT interim results.
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
Etiology and Diagnosis of Bullous Pemphigoid
Professor Joost Meijer discusses the complex etiology and diagnosis of BP
